Improved efficacy in gene therapy of hemophilia A using an AAV6 pseudo-typed FVIII vector

被引：0
|
作者：
Jiang, HY [1 ]
Patarroyo-White, S [1 ]
Nagy, D [1 ]
Vargas, J [1 ]
Scallan, C [1 ]
Liu, TY [1 ]
Powell, S [1 ]
Wright, F [1 ]
Couto, L [1 ]
机构：
[1] Avigen Inc, Alameda, CA USA
来源：
MOLECULAR THERAPY | 2003年 / 7卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
471
引用
收藏
页码：S184 / S184
页数：1
相关论文
共 50 条
  • [1] Hemophilia A gene therapy in mouse and dog models using an AAV-FVIII vector.
    Couto, L
    Scallan, C
    Jiang, HY
    Qian, XB
    Patarroyo-White, S
    Parker, A
    Liu, TY
    Chen, HF
    Powell, S
    Wright, F
    Tinlin, S
    Webster, S
    Lillicrap, D
    Arruda, V
    High, K
    Kay, M
    McClelland, A
    BLOOD, 2002, 100 (11) : 117A - 117A
  • [2] AAV Vector and Transgene Modifications for Improved Efficacy in Hemophilia Gene Therapy with Continuous Expression of FVIIa
    Margaritis, Paris
    Faella, Armida
    Pavani, Giulia
    Couto, Linda
    Zhou, Shangzhen
    High, Katherine A.
    MOLECULAR THERAPY, 2012, 20 : S90 - S90
  • [3] Transcriptional activity of recombinant AAV-FVIII vectors for gene therapy of Hemophilia A
    Kelly, EJ
    Jacobson, DR
    Dekker, SL
    Godwin, SG
    Lippa, M
    Lustig, KH
    Rogers, L
    Sandalon, Z
    Stepan, T
    Thompson, SA
    Burstein, H
    Peluso, RW
    Lynch, CM
    MOLECULAR THERAPY, 2003, 7 (05) : S394 - S395
  • [4] Biopotency and efficacy of a FVIII gene therapy construct in hemophilia A mice
    Hoellriegl, Werner
    Weiller, Markus
    Kopic, Alexandra
    Gritsch, Herbert
    Gangadharan, Bagirath
    Falkner, Falko G.
    Monahan, Paul E.
    Rottensteiner, Hanspeter
    Scheiflinger, Edrich
    Turecek, Marietta
    HAEMOPHILIA, 2016, 22 : 34 - 34
  • [5] Development of a Synthetic AAV Vector for Gene Therapy of Hemophilia in Children
    Shoti, Jakob
    Qing, Keyun
    Srivastava, Arun
    MOLECULAR THERAPY, 2022, 30 (04) : 332 - 332
  • [6] In vitro aided identification of AAV6 as the best vector for gene transfer into porcine myocardium
    Ksienzyk, J.
    Raake, P.
    Schlegel, P.
    Shan, C.
    Weber, C.
    Kleinschmidt, J. A.
    Katus, H. A.
    Mueller, O. J.
    HUMAN GENE THERAPY, 2010, 21 (10) : 1469 - 1469
  • [7] Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia
    Hauck, B
    Xu, RR
    Xie, J
    Wu, WM
    Ding, QL
    Sipler, M
    Wang, HL
    Chen, L
    Wright, JF
    Xiao, WD
    HUMAN GENE THERAPY, 2006, 17 (01) : 46 - 54
  • [8] Engineering of a High-Activity FVIII-BDD Gene Therapy Vector with High AAV-Packaging Efficiency for Hemophilia A
    Bin, Qu
    Li, Na
    Zhu, Xi
    Luo, Wenjing
    Li, Hongyu
    Yang, Xingyu
    Tian, Shin-Shay
    Zhao, Xiaoping
    MOLECULAR THERAPY, 2024, 32 (04) : 517 - 518
  • [9] Airway Mucus Minimally Impedes Aav6 For Inhaled Lung Gene Therapy
    Duncan, G. A.
    Kim, N.
    Colon-Cortes, Y.
    West, N. E.
    Aslanidi, G.
    Livraghi-Butrico, A.
    Srivastava, A.
    Boucher, R. C.
    Hanes, J.
    Suk, J. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [10] Transcriptional activity. of recombinant: AAV-FVIII vectors or gene therapy of Hemophilia A.
    Kelly, EJ
    Jacobson, DR
    Dekker, SL
    Godwin, SG
    Lippa, MS
    Lustig, KH
    Rogers, LC
    SAndalon, Z
    Stepan, TM
    Thompson, SA
    Burstein, H
    Peluso, RW
    Dorner, AJ
    Lynch, CM
    BLOOD, 2002, 100 (11) : 485B - 485B
12345